Clinical Trials Logo

Clinical Trial Summary

The NIREUS study aims to demonstrate angiographic non-inferiority for the BioNIR Ridaforolimus Eluting Coronary Stent System (hereafter referred to as BioNIR) in comparison to the Resolute zotarolimus-eluting stent (hereafter referred to as Resolute). The trial hypothesis is that the BioNIR is non-inferior to the Resolute for the primary endpoint of angiographic in-stent late loss at 6 months.


Clinical Trial Description

This is a prospective, multi-center, single-blind, two-arm, 2:1 randomized clinical trial. Randomization will be stratified by the presence of medically treated diabetes vs. no medically treated diabetes and by site. Lesions planned to be treated must be declared and recorded at time of randomization. Angiographic follow-up will be performed at 6 months. Clinical follow-up will be performed at 30 days, 6 months, and 1, 2, 3, 4, and 5 years post randomization. The Primary Endpoint is in-stent late loss at 6 months as measured by the angiographic core laboratory. Angiographic Secondary Endpoints to be evaluated at 6 months are: - In-segment late loss - Follow-up percent diameter stenosis (in-stent and in-segment) - Binary restenosis (in-stent and in-segment) - Length and patterns of angiographic restenosis (Mehran classification) Clinical Secondary Endpoints to be evaluated at 30 days, 6 months, and 1, 2, 3, 4 and 5 years, except as noted, are: - Device, Lesion, and Procedure Success at time of baseline procedure - Target lesion failure (TLF; the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR) - Major adverse cardiac events (MACE; the composite rate of cardiac death, any MI or ischemia-driven TLR) - Target vessel failure (TVF; the composite rate of death, target vessel-related MI, or ischemia-driven TVR) - Overall Mortality - Cardiac Death - Myocardial Infarction - Target Vessel Related MI - Ischemia-driven TLR - Ischemia-driven TVR - Stent Thrombosis (ARC definite and probable) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01995500
Study type Interventional
Source Medinol Ltd.
Contact
Status Completed
Phase Phase 2
Start date March 19, 2014
Completion date June 17, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05133843 - Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Implantation (TAVI) in Patients With Severe Symptomatic Aortic Valve Stenosis N/A
Completed NCT01205776 - EXCEL Clinical Trial N/A
Completed NCT01332591 - Multivessel Disease Diagnosed at the Time of PPCI for STEMI: Complete Revascularization Versus Conservative Strategy. N/A
Completed NCT00739466 - Biorest Liposomal Alendronate With Stenting sTudy (BLAST) Phase 2
Completed NCT01182428 - XIENCE V: SPIRIT WOMEN Sub-study Phase 4
Completed NCT00531011 - EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease Phase 4
Completed NCT01310309 - EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease Phase 4
Not yet recruiting NCT06052670 - Functional Diagnostic Accuracy of Ultrasonic Flow Ratio in Assessment of Coronary Artery Lesions
Completed NCT05509296 - Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease N/A
Not yet recruiting NCT05393882 - Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency
Recruiting NCT06397820 - Relation Between AI-QCA and Cardiac PET
Active, not recruiting NCT01960504 - First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II) N/A
Completed NCT01721096 - XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
Active, not recruiting NCT01342822 - Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization Phase 4
Completed NCT01205789 - EXCEL Clinical Trial (Universal Registry) N/A
Recruiting NCT05532605 - Effects of Mindfulness Based Therapy on Illness and Depression in Cardiac Rehab Phase-i N/A
Completed NCT02066623 - Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold
Not yet recruiting NCT02946320 - Optimal Predilatation Technique for BVS Implantation Phase 3
Terminated NCT01136915 - Kidney Damage In Patients With Severe Fall In eGFR Phase 4
Completed NCT01249027 - XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study